

# The GOG Highlight Reel Fall 2023

---

A GOG Foundation, Inc. Educational Program

Thursday, November 30, 2023



# Moderators



**Thomas Herzog, MD**

University of Cincinnati,  
Cincinnati, Ohio



**Bradley J. Monk, MD**

HonorHealth, University of  
Arizona College of Medicine,  
Creighton University School of  
Medicine at St. Joseph's  
Hospital

Phoenix, AZ



**GOG**  
**Highlight Reel**



**OUR MISSION**  
To conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies



**OUR VISION**  
To be the premier collaborative network for transformative research in gynecologic malignancies



**GOG**  
**Highlight Reel**

# LEARNING OBJECTIVES

Upon completion of the activities in this series, learners will demonstrate:

**THE OVERALL OBJECTIVE FOR THIS SESSION IS TO SHOWCASE CLINICAL TRIALS AND OTHER NEWSWORTHY EDUCATION FROM MAJOR MEDICAL MEETINGS THROUGHOUT THE YEAR**

**Greater competence related to**

- Selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers

**Increased knowledge regarding**

- The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
- The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
- The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers

# GOG FACULTY DISCLOSURE INFORMATION

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
<b>Planning Disclosures</b>			
Thomas Herzog, MD	Moderator		Astra Zeneca; Caris; Clovis; Eisai; Epsilogen; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics: Scientific Advisory Boards
Bradley J. Monk, MD	Moderator		Honoraria: Consulting/Speaker: Agenus, Akeso, AstraZeneca, Aravive, Clovis, Easai, Elevar, Genmab/Seattle Genetics, GOG Foundation. Gradalis, Iovance, Karyopharm, Merck, McKesson, Mersana, Myriad, Novocure, Pfizer, Roche/Genentech, Sorrento, Tesaro/GSK, VBL
<b>Speaker Disclosures</b>			
Robert Coleman, MD	Speaker		Agenus; Alkermes, Inc.; AstraZeneca; Clovis Oncology, Inc.; Deciphera Pharmaceuticals Inc.; EISAI INC.; Genentech USA, Inc.; GlaxoSmithKline; Gradalis; Mersana; Novocure Inc.; oncxerna; Regeneron Pharmaceuticals: Consultant AbbVie; Immunogen; Janssen Biotech, Inc.; Merck; Novartis; Onxeo; Seagen Inc.: Grant / Contract Vbl: Data And Safety Monitoring
Thomas Herzog, MD	Speaker		Astra Zeneca; Caris; Clovis; Eisai; Epsilogen; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics: Scientific Advisory Boards
Bhavana Pothuri, MD	Speaker		AstraZeneca; Celsion; Immunogen; Merck; Mersana; Seattle Genetics; Sutro; Takada; Tesaro; Clovis Oncology: Research funding support/ Ad Board fees: Eisai, Lily, GOG Foundation: Advisory Board
Leslie Randall, MD	Speaker		AstraZeneca Pharmaceuticals LP; Clovis Oncology, Inc.; GlaxoSmithKline; Immunogen; Seagen Inc.: Consultant
Ritu Salani, MD, MBA	Speaker		Merck; Eisai; GSK; Seagen; Regeneron; Karyopharm; Immunogen: Ad board/Consultant Up To Date; Elsevier: Writer
Angeles Alvarez Secord, MD, MHSc	Speaker		AbbVie; Aravive; AstraZeneca; Clovis Oncology, Inc.; Eisai; Genentech; GSK; Merck; National Cancer Trial Network; Oncoquest; Seagen Inc; Tapimmune; VBL Therapeutics: Grant / Contract Immunogen; Myriad Genetic Laboratories, Inc.: Consultant AAOGF; GOG Foundation; SGO: Other
Brian Slomovitz, MD	Speaker		Abbvie; AstraZeneca; Clovis; GSK; Genentech; Merck; Myriad: Consultant
Michelle N Small, MPH	Staff	x	
Jill Reese	Staff	x	

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations.**

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

# GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

## Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

## AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of **2.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.



# COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support and sponsorship associated with this Symposium:

AstraZeneca

Genelux

GSK

Acrivon

Seagen, Inc. | Genmab

R-Pharm

ImmunoGen

# FACULTY



**Angeles Alvarez-Secord, MD, MHSc**, Duke Cancer Center Institute, Durham, North Carolina, USA

**Robert Coleman, MD**, Texas Oncology, Vaniam Group, Houston, Texas, USA

**Bhavana Pothuri, MD**, NYU Langone, New York City, New York, USA

**Leslie Randall, MD, MAS** Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA

**Ritu Salani, MD, MS**, UCLA Medical Center, Los Angeles, California, USA

**Brian Slomovitz, MD**, Mount Sinai Medical Center, Miami Beach, Florida, USA

# AGENDA

6:30 pm – 6:35 pm

## **Welcome & Introductions**

Thomas Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA

Bradley Monk, MD, Director, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital and HonorHealth Phoenix, Arizona, USA

6:35 pm – 7:25 pm

## **Cervical Cancer – *New Data in CCRT, 1<sup>st</sup> Line, 2<sup>nd</sup> Line and How It Impacts Your Clinical Practice***

Leslie Randall, MD, Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA

Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA

Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA

7:25 pm – 8:05 pm

## **The Evolution of Ovarian Cancer**

Angeles Alvarez-Secord, MD, MHSc, Director of Gynecologic Oncology Clinical Trials, Duke Cancer Center Institute, Durham, North Carolina, USA

Robert Coleman, MD, Texas Oncology, Vaniam Group, Houston, Texas, USA

8:05 pm – 8:55 pm

## **Uterine Cancer, The Knowns and Unknowns – A Heated Discussion on Pivotal Changing Data**

Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA

Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA

Thomas Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA

Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA

8:55 pm – 9:00 pm

## **Wrap Up and Announcement of Next GOG Highlight Reel**

Thomas Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA